AssetMark’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.81K Buy
97
+29
+43% +$1.12K ﹤0.01% 2840
2026
Q2
$2.48K Hold
68
– – ﹤0.01% 2905
2026
Q1
$1.9K Buy
68
+12
+21% +$393 ﹤0.01% 2870
2025
Q4
$2.1K Sell
56
-23
-29% -$756 ﹤0.01% 2764
2025
Q3
$2.18K Buy
79
+23
+41% +$792 ﹤0.01% 2607
2025
Q2
$1.77K Buy
56
+19
+51% +$611 ﹤0.01% 2468
2025
Q1
$1.23K Hold
37
– – ﹤0.01% 2264
2024
Q4
$1.27K Buy
37
+5
+16% +$172 ﹤0.01% 2195
2024
Q3
$1.28K Hold
32
– – ﹤0.01% 1952
2024
Q2
$965 Hold
32
– – ﹤0.01% 1853
2024
Q1
$1.08K Sell
32
-7
-18% -$225 ﹤0.01% 1665
2023
Q4
$1.26K Buy
+39
New +$1.09K ﹤0.01% 1604

Other funds holding HRMY

AssetMark's HRMY Position: Q3 2026 in Review

AssetMark increased its Harmony Biosciences (HRMY) stake by 43% in Q3 2026, buying an estimated $1.12K and bringing the position to 97 shares worth $3.81K. The position accounts for ﹤0.01% of the portfolio, ranked #2840.

AssetMark first reported a position in HRMY in Q4 2023 and has held it in 12 quarters since. 279 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

  • AssetMark held 97 shares of Harmony Biosciences worth $3.81K as of Q3 2026.
  • AssetMark bought 29 Harmony Biosciences shares in Q3 2026, an estimated $1.12K.
  • Harmony Biosciences made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2840 holding.
  • AssetMark first reported a position in Harmony Biosciences in Q4 2023 and has held it in 12 quarters since.
  • 279 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.